March 6, 2008. bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in Singapore. This 38th subsidiary is another milestone for the company’s international expansion. It will also advance bioMérieux’s Asian development strategy, following recent announcements of joint ventures in China and Japan.
The new subsidiary will host bioMérieux’s ASEAN team, supporting all of the ASEAN countries, Korea, Australia and New Zealand. The Singapore-based team will consist initially of Marketing managers, Application Specialists and Field Service Engineers supporting bioMérieux distributors in the ASEAN countries, as well as Regional Business Managers.
“We are taking one more step to increase our presence in Asia-Pacific, the region that will drive global growth in the 21st century,” stated Stéphane Bancel, bioMérieux Chief Executive Officer. “The expansion of our international network is critical for our company’s long-term sales growth and this greater proximity allows us to better serve our customers. Every time we open a new subsidiary, not only do we bolster our commercial operations with local presence, but we also strengthen our position as a business development partner for companies with innovative technologies,” he added.
About bioMérieux
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Eurolist by Euronext. For more information, visit http://www.biomerieux.com/.
Investor Relations
bioMérieux
Hervé Laurent
Tel: + 33 4 78 87 22 37
investor.relations@eu.biomerieux.com
LT Value
Nancy Levain
Tel: + 33 1 44 50 39 30
nancy.levain@ltvalue.com
Media Relations
bioMérieux
Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08
media@eu.biomerieux.com
Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr
Tiphaine Hecketsweiler
Tel: + 33 1 53 70 74 59
thecketsweiler@image7.fr